Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have received at least one infusion of a medicine called lisocabtagene maraleucel (also known as liso-cel) as a standard, approved treatment for Mantle Cell Lymphoma (a type of blood cancer), using the dose and product approved by the US FDA
Who may not be able to join:
- People who were taking part in another research or experimental study at the time they received their liso-cel infusion
- People who received a version of the CAR T-cell product that did not meet the required quality or manufacturing standards
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Adverse events (AEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.